Increasing human papillomavirus (HPV) vaccination rate among
adolescent and young adult males in a primary care setting
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BACKGROUND

METHODS

RESULTS

 Nationally, 8.3% of males ages 13-17 received
the first dose of the HPV vaccine in 2011

 Eligible participants were contacted the day prior to their appointment or approached
immediately prior to seeing their doctor, and were informed of the study

 n=30 (24 males and 6 parents completed the survey)
 70% African American

 Studies have found lower levels of knowledge
and awareness about HPV and the vaccine
among males and their parents, as compared to
females and their parents
 Providers are less likely to recommend a health
care service (i.e. a vaccine) if they believe that
the patient’s understanding is low, given the
multiple competing demands of the brief clinical
encounter.
 Studies have shown that when adolescent
females and their parents are briefly educated
about the HPV vaccine, intentions to vaccinate,
from both the perspective of the provider and
the patient, greatly improve.

 Informed consent obtained for those who agreed to participate

 70% (n=21) had heard of HPV

 Informational aid was presented to participants with the option to review it together or alone

 67% (n=20) had heard of the HPV vaccine

 Post-education survey to measure:
 Intentions to talk to their physician about HPV and the vaccine
 Intent to receive the vaccine
 Likelihood of receiving the vaccine at the visit
 Identification of knowledge disseminated about HPV and the vaccine

 Thoughts and feelings about the vaccine varied:
 64% provided a specific reason why the vaccine
was important, such as:

STUDY PURPOSE
 To increase HPV vaccination rates among
adolescent males through the use of an
informational aid designed to increase
knowledge and favorable attitudes about HPV
vaccination

 All participants were debriefed about incorrect answers and given opportunity to ask more
questions
 Medical chart audits were performed the following day to determine vaccination occurrence

RECRUITMENT

 11-26 year old males (and accompanying
parents of males, if applicable)

WHO CAN GET
THE VACCINE?

Pre-visit
No call back (n=5)
Cognitive Dysfunction (n=3)
Late/Seen Quickly (n=14)
Study Staff Not Available
(n=19)

Doctors recommend that all girls and
boys start the HPV vaccine series when
they are between 11–12 years old. But
anyone up to 26 years old can get the
vaccine.

ARE THERE ANY
RISKS TO GETTING
THE VACCINE?
The vaccine has been shown to be safe
and effective in both males and females.
Side effects, if any, are usually mild and
include pain and swelling at the arm,
fever, dizziness or fainting, and nausea.

 13% did not provide a response

FOR MORE
INFORMATION
Check out the CDC’s (Center for Disease
Control and Prevention) website at:
www.cdc.gov/std/hpv/stdfact-hpvand-men.htm
If you have any questions about the
content of this pamphlet, please contact
us at:
Department of Family and
Community Medicine
Thomas Jefferson University
833 Chestnut St, Suite 301
Philadelphia, PA 19107
Phone: 215-955-7190

WE DON’T HAVE
TO WORRY
ABOUT HPV,
DO WE?
Jefferson Family
Medicine Associates

During Visit Time
Declined (n=8)
No show/rescheduled (n=29)
Late or Seen Quickly (n=14)
Consented
n=30

 No history of HPV vaccination, as reported in
the EMR
 Had a scheduled appointment at Jefferson
Family Medicine Associates

 23% provided a specific reason why the vaccine
was not important:

INFORMATIONAL AID

The vaccine was approved for females
in 2006 and for males in 2011.

STUDY ELIGIBILITY

Vaccinated
n=11

“I believe it is important because there are no risks
and it will only serve to protect myself and others”

“I am not sexually active, nor have I ever been,
and I plan on waiting until marriage”

Eligible via Chart
Audit
n=108

 Evaluate the educational aid for feasibility of
use in a primary care setting, interest among
patients for participating, and increases in
intentions to vaccinate among patients and
providers

“After receiving more education about HPV, I
believe it is more important to get the vaccine”

 Two-thirds of participants felt comfortable speaking to
their physicians about the vaccine on the day of their
visit and over half thought it would be important to get
the HPV vaccine that day.
 37% of patients were vaccinated; those who indicated
that it was important to be vaccinated were more likely
to start the vaccine series

CONCLUSIONS
 Short intervention is feasible in a primary care setting
 Males see lack of sexual activity as a reason not to
vaccinate, more education needed in this area
 Areas for future work/follow-up:
 Expanding investigation of HPV vaccination rates
among adolescent males in other primary care
settings to better determine applicability
 Assess the retention of males who initiated their
vaccine and proportion who complete the series
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